Compliance with biologic therapies for rheumatoid arthritis: Do patient out‐of‐pocket payments matter?
Authors:
Open Access
- 29 September 2008
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (10) , 1519-1526
Abstract
Objective: To assess the impact of patient out‐of‐pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA).Methods: An inception cohort of RA patients with pharmacy claims for etanercept or adalimumab during 2002–2004 was selected from an insurance claims database of self‐insured employer health plans (n = 2,285) in the US. Adherence was defined as medication possession ratio (MPR): the proportion of the 365 followup days covered by days supply. Persistence was determined using a survival analysis of therapy discontinuation during followup. Patient OOP cost was measured as the patient's coinsurance and copayments per week of therapy, and as the proportion of the total medication charges paid by the patient. Multivariate linear regression models of MPR and proportional hazards models of persistence were used to estimate the impact of cost, adjusting for insurance type and demographic and clinical variables.Results: Mean ± SD OOP expenditures averaged $7.84 ± $14.15 per week. Most patients (92%) paid less than $20 OOP for therapy/week. The mean ± SD MPR was 0.52 ± 0.31. Adherence significantly decreased with increased weekly OOP (coeff = −0.0035, P < 0.0001) and with a higher proportion of therapy costs paid by patients (coeff = −0.8794, P < 0.0001), translating into ∼1 week of therapy lost per $5.50 increase in weekly OOP. Patients whose weekly cost exceeded $50 were more likely to discontinue than patients with lower costs (hazard ratio 1.58, P < 0.001).Conclusion: Most patients pay less than $20/week for biologics, but a small number have high OOP expenses, associated with lower medication compliance. The adverse impact of high OOP costs on adherence, persistence, and outcomes must be considered when making decisions about increasing copayments.Keywords
This publication has 20 references indexed in Scilit:
- Prescription Drug Cost SharingJAMA, 2007
- Infliximab treatment maintains employability in patients with early rheumatoid arthritisArthritis & Rheumatism, 2006
- Pharmacy Benefits and the Use of Drugs by the Chronically IllJAMA, 2004
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and SpendingNew England Journal of Medicine, 2003
- Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costsClinical Therapeutics, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical UtilizationMedical Care, 2001
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000